Corporate Magazine 2012 - Boehringer Ingelheim

We are satisfied with this result, as the successful operative business developmentoverall was negatively impacted by a multitude of one-off and extraordinary effects.Behind these effects are decisions which we have taken in order to preparethe group of companies for a changing business environment. With these measureswe have created a good starting position for ourselves for the years ahead.Our financial management aims to ensure liquidity, limit financial risks and optimisethe cost of capital. It is noteworthy that it allows the overall financing of thegroup of companies to maintain our independent, organic growth.Our fields of businessBoehringer Ingelheim divides its business activities into the areas Human Pharmaceuticals,Biopharmaceuticals and Animal Health.Human PharmaceuticalsOur Human Pharmaceuticals business’s sales were EUR 13,081 million, therebyshowing gratifying growth of around + 12%, (currency-adjusted + 7.7%). With an89% share of total sales, our Human Pharmaceuticals business (including PrescriptionMedicines and Consumer Health Care) is Boehringer Ingelheim’s largestbusiness area.Prescription MedicinesIn this business, the business area Prescription Medicines generated sales growth of+ 13%, amounting to EUR 11,405 million. In 2012, our anticoagulant pradaxa®,with sales of EUR 1.1 billion, exceeded the EUR 1 billion sales mark for the first time.The products spiriva® (EUR 3.6 billion), already established for 10 years, micardis®(EUR 1.6 billion) and combivent® (EUR 883 million) continued to grow.In addition, trajenta®, for the treatment of type 2 diabetes, has significant salespotential. trajenta® is marketed with Eli Lilly and Company within the frameworkof our strategic alliance in the field of diabetes. We consider it very disappointingthat trajenta®, a medication developed and manufactured in Germany, is preciselynot available in Germany for patients with type 2 diabetes. We remain convincedthat trajenta® has a distinct, patient-relevant, added benefit and we seeour position confirmed by positive therapeutic experiences in some 40 countriesaround the world.12Boehringer Ingelheim annual report 2012